2. Search Result
Search Result
Results for "

murine melanoma

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

3

Biochemical Assay Reagents

5

Peptides

1

Inhibitory Antibodies

13

Natural
Products

2

Isotope-Labeled Compounds

1

Click Chemistry

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-146245C
    ODN 1826 sodium
    5+ Cited Publications

    CpG 1826 sodium

    		 Toll-like Receptor (TLR) Apoptosis NO Synthase Cardiovascular Disease Inflammation/Immunology Cancer
    ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma .
    ODN 1826 sodium
  • HY-117037
    FR900359
    4 Publications Verification

    		 Apoptosis ERK Cardiovascular Disease Cancer
    FR900359 is a depsipeptide selective inhibitor of Gαq/11/14 in mammalia, can inhibits ERK pathway. FR900359 suppresses the proliferation of melanoma cells and decreases of blood pressure. FR900359 also protected against airway hyperreactivity in murine models of allergen sensitization in Ovalbumin, low endotoxin (HY-W250978A)-induced sensitization model of asthma. FR900359 can be used for cancer and cardiovascular disease research .
    FR900359
  • HY-P11307
    Biotin-epoxomicin

    		Proteasome Cancer
    Biotin-epoxomicin is a Proteasome subunit binder. Biotin-epoxomicin serves as an affinity reagent for identifying proteasomal catalytic subunits, and facilitates affinity purification of active proteasomal subunits for LC-MS identification. Biotin-epoxomicin can be used to study solid tumors derived from B16 melanoma .
    Biotin-epoxomicin
  • HY-164278
    diABZI-V/C-Mal

    		STING Cathepsin Cancer
    diABZI-V/C-Mal is a STING agonist (with a STING EC50 of 314 nM in TH1 dual reporter cells) and a Cathepsin B substrate. diABZI-V/C-Mal activates STING, thereby triggering the IRF3 signaling pathway. diABZI-V/C-Mal is cleaved by Cathepsin B to regenerate diABZI-NH2 .
    diABZI-V/C-Mal
  • HY-159069
    Zymosan (ZM), 95%

    		Toll-like Receptor (TLR) TNF Receptor Connexin Infection Cancer
    Zymosan (ZM), 95% is a yeast cell wall-derived carbohydrate-rich preparation and immunomodulator. Zymosan (ZM), 95% binds to and activates TLR-2, TLR-4, and Dectin-1 receptor to trigger downstream signaling pathways. Zymosan (ZM), 95% upregulates TLR-2, TLR-4, and TNF-α mRNA expression, increases serum TNF-α levels, and stimulates splenocyte number and viability in mice. Zymosan (ZM), 95% attenuates melanoma growth progression, modulates macrophage marker gene expression, and mediates phagocytosis, ROS generation, and cytokine production. Zymosan (ZM), 95% reduces Connexin 43 protein and mRNA levels, inhibits gap junctional intercellular communication, and induces proinflammatory factor production in human corneal cells. Zymosan (ZM), 95% induces peritoneal inflammation in mice, functions as a drug carrier, and supports fibroblast cell attachment in hydrogel formulations. Zymosan (ZM), 95% can be used for the research of melanoma, tumors, fungal keratitis, ocular surface inflammatory disorders, and peritoneal inflammation .
    Zymosan (ZM), 95%
  • HY-124309
    NHI-2

    		Lactate Dehydrogenase Apoptosis Cancer
    NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 14.7 µM. NHI-2 shows selective for LDHA over LDHB (IC50 = 55.8 µM). NHI-2 is an efficient anti-glycolytic agent. NHI-2 enhances apoptosis, induces cell cycle arrest at S and G2 phases. NHI-2 has a broad spectrum anti-proliferative activity in cancer cells. NHI-2 affects extracellular acidification rate and ATP production. NHI-2 suppresses tumor growth in murine B78 melanoma tumor model .
    NHI-2
  • HY-N10423
    Cubebin

    (-)-Cubebin

    		 Cholinesterase (ChE) Bacterial Fungal Parasite p38 MAPK Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Cubebin ((-)-Cubebin), a dibenzyl butyrolactone lignan, is an orally active AChE inhibitor. Cubebin binds to active sites of NF-κB, TNF-α, and TGF-β1 via hydrogen and hydrophobic interactions, obstructing critical residues to inhibit pro-inflammatory or renal fibrosis-related activity. Cubebin enhances p38 MAPK phosphorylation to increase tyrosinase gene expression, stimulating melanogenesis via elevated tyrosinase activity, expression, and mRNA levels. Cubebin reduces oxidative stress via enhanced endogenous antioxidant enzyme activity and inhibited lipid peroxidation, regulates lipid metabolism, improves glycemic control, and exerts renoprotective effects via reduced renal dysfunction markers and improved renal architecture. Cubebin shows antimicrobial activity. Cubebin exerts larvicidal activity against Angiostrongylus cantonensis larvae, with no cytotoxicity toward monkey or human cell lines or Caenorhabditis elegans. Cubebin can be used for the research of diabetic nephropathy, melanoma, colon adenocarcinoma, neuroangiostrongyliasis, Alzheimer’s disease (AD) and depression .
    Cubebin
  • HY-N1098
    Velutin

    		Tyrosinase p38 MAPK NF-κB Bacterial Infection Metabolic Disease Inflammation/Immunology
    Velutin is a flavonoid. Velutin can be extracted from mistletoe. Velutin inhibits mushroom Tyrosinase activity with an IC50 of 910.1 μM. Velutin inhibits p38 phosphorylation, the NF-κB pathway and the MAPK pathway. Velutin prevents articular cartilage degeneration and subchondral bone loss. Velutin slows down the progression of intervertebral disc degeneration. Velutin exhibits inhibitory effects on melanogenesis, skin whitening, anti-inflammatory, anti-allergic, anti-oxidant and antibacterial activities. Velutin can be used in studies related to pigmented diseases, osteoarthritis and intervertebral disc degeneration .
    Velutin
  • HY-N6829
    Retusin

    Quercetin-​3,​3',​4',​7-​tetramethylether

    		 Tyrosinase Fungal SARS-CoV Apoptosis Reactive Oxygen Species (ROS) Infection Neurological Disease Metabolic Disease Inflammation/Immunology
    Retusin (Quercetin-3,3',4',7-tetramethylether) is a tyrosinase inhibitor, with IC50 values of 50.9 μM and 51.8 μM against mushroom and intracellular tyrosinase, respectively. Retusin also acts as a free radical scavenger, melanogenesis inhibitor, anti-apoptosis agent, neuroprotective agent, antiemetic, antifungal agent, and antiviral agent. Retusin scavenges ABTS• + and DPPH• free radicals. Retusin can be used in studies related to hyperpigmentation, vomiting, Aspergillus niger infection, and COVID-19 infection .
    Retusin
  • HY-W272217S
    Octacosane-d58

    n-Octacosane-d58; NSC 5549-d58

    		 Bacterial Endogenous Metabolite Cancer
    Octacosane-d58 is the deuterium labeled Octacosane . Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l .
    Octacosane-d58
  • HY-130115
    IACS-8803

    		STING Cancer
    IACS-8803 is a highly potent cyclic dinucleotide STING agonist with robust systemic antitumor efficacy .
    IACS-8803
  • HY-174830
    GJ19

    		PD-1/PD-L1 Cancer
    GJ19 is a PD-L1 inhibitor with an IC50 of 32.06 nM. GJ19 can effectively bind to human/murine PD-L1 protein with Kd values of 171 and 290 nM, respectively. GJ19 concentration-dependently promotes HepG2 cell mortality in a co-culture model of HepG2/hPD-L1 and Jurkat T/hPD-1 cells. GJ19 effectively suppresses tumor growth in a B16-F10 melanoma mouse model. GJ19 can be used for the study of tumor immunotherapy .
    GJ19
  • HY-W272217
    Octacosane

    n-Octacosane; NSC 5549

    		 Endogenous Metabolite Bacterial Inflammation/Immunology Cancer
    Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l .
    Octacosane
  • HY-124136
    WYC-209
    1 Publications Verification

    		 RAR/RXR Apoptosis Autophagy Cancer
    WYC-209, a synthetic retinoid, is a retinoic acid receptor (RAR) agonist. WYC-209 induces apoptosis primarily via the caspase 3 pathway (IC50=0.19 μM for inmalignant murine melanoma TRCs), and has long-term effects with little toxicity .
    WYC-209
  • HY-W001939
    4-Acetylbenzoic acid

    		Biochemical Assay Reagents Cancer
    4-Acetylbenzoic acid is a Zn(II) complex. 4-Acetylbenzoic acid is a derivative of benzoic acid that is commonly used in chemical synthesis. 4-Acetylbenzoic acid has an IC50 of 331.3 μM in murine L929 fibroblasts and an IC50 of 176 μM in metastatic melanoma B16 F10 cell lines .
    4-Acetylbenzoic acid
  • HY-P991455
    PTX-35

    		TNF Receptor Cancer
    PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 lambda2, Isotype Control (HY-P990096) .
    PTX-35
  • HY-N7717
    (-)-N-methylcoclaurine

    (–)-(1R)-N-methylcoclaurine

    		 Drug Derivative Metabolic Disease
    (-)-N-methylcoclaurine ((-)-(1R)-N-methylcoclaurine) is a benzylisoquinoline alkaloid and melanogenesis inhibitor with an IC50 of 6.5 μM that can be found in the flower buds of Nelumbo nucifera. (-)-N-methylcoclaurine inhibits theophylline-stimulated melanogenesis in melanoma cells. (-)-N-methylcoclaurine can be used for the research of skin hyperpigmentation disorders .
    (-)-N-methylcoclaurine
  • HY-N8712
    Umckalin

    		p38 MAPK JNK ERK TNF Receptor Interleukin Related PI3K Akt Inflammation/Immunology
    Umckalin is Coumarin (HY-N0709) derivative that exhibits anti-inflammatory properties. Umckalin reduces phosphorylation of p38 MAPK, JNK, and ERK, lowers TNF-α, IL-6, IL-1β, NO, and PGE2 production. Umckalin can be used for the research of chronic inflammatory diseases .
    Umckalin
  • HY-172200
    PD-L1/HDAC6-IN-1

    		PD-1/PD-L1 HDAC Inflammation/Immunology Cancer
    PD-L1/HDAC6-IN-1 is an orally active dual inhibitor of PD-L1 and HDAC6, with IC50 values of 26.8 nM and 78 nM, respectively. PD-L1/HDAC6-IN-1 binds to human and murine PD-L1 proteins with high affinity, while it reduces STAT3 phosphorylation and downregulates PD-L1 expression by inhibiting HDAC6, thus blocking the PD-1/PD-L1 interaction. PD-L1/HDAC6-IN-1 exhibits potent anti-tumor activity in a mouse melanoma model. PD-L1/HDAC6-IN-1 is suitable for research on tumor immune regulation related to melanoma .
    PD-L1/HDAC6-IN-1
  • HY-W654372
    Tigloyl-L-carnitine chloride

    		Endogenous Metabolite Cancer
    Tigloyl-L-carnitine (chloride) is a short-chain acylacarnitine containing tiglic acid and L-carnitine. Tigloyl-L-carnitine (chloride) is increased in plasma in certain melanoma xenograft murine models. Tigloyl-L-carnitine (chloride) can be studied in research on melanoma .
    Tigloyl-L-carnitine chloride
  • HY-10615
    A-620223
    1 Publications Verification

    		 PARP Cancer
    A-620223 is a PARP-1 inhibitor with a Ki of 8 nM against PARP-1 and EC50 of 3 nM in a whole cell assay. A-620223 demonstrates good in vivo efficacy in a B16F10 subcutaneous murine melanoma model in combination with Temozolomide (TMZ) (HY-17364) and in an MX-1 breast xenograph model in combination with Cisplatin (HY-17394). A-620223 can be used for the studies of melanoma and breast cancer .
    A-620223
  • HY-113484
    Leukotriene B5

    LTB5

    		 Leukotriene Receptor Cancer
    Leukotriene B5 (LTB5) is a leukotriene with diverse biological activities. It is a metabolite of eicosapentaenoic acid formed through the 5-lipoxygenase (5-LO) pathway. LTB5 increases contraction of bullfrog lung strips ex vivo in a concentration-dependent manner. In vivo, LTB5 (100 nM) reduces tumor volume in mice injected with Tm1 murine melanoma cells. LTB5 also elicits chemokinesis and lysosomal enzyme release from polymorphonuclear leukocytes (PMNLs) 20- to 30-fold less, and induces platelet aggregation 8-fold less, potently than LTB4.
    Leukotriene B5
  • HY-172533
    3′,5′-DiOA-dC

    		STING Cancer
    3’,5’-DiOA-dC is a hydrophobic nucleotide lipid and a ligand for the STING agonist c-di-GMP (CDG). 3’,5’-DiOA-dC can assemble with CDG and form stable cyclic dinucleotide nanoparticles via various supramolecular forces driven by molecular recognition. 3’,5’-DiOA-dC can decrease tumor weight and volume, increase CD8 T cell, neutrophils as well as NK cell counts in tumor microenvironment in combination with CDG. 3’,5’-DiOA-dC also increases the levels of TNF-α and IFN-γ in murine melanoma model .
    3′,5′-DiOA-dC
  • HY-15616
    BMS-470539

    		Melanocortin Receptor Cancer
    BMS-470539 is a synthetic MC-1R agonist with potent anti-inflammatory properties. BMS-470539 selectively activates human and murine MC-1R with EC50 values ??of 16.8 nM and 11.6 nM, respectively. In vitro studies have shown that BMS-470539 is able to dose-dependently inhibit TNF-alpha-induced NF-kB activation in human melanoma cells expressing MC-1R. In vivo, subcutaneous injection of BMS-470539 into BALB/c mice effectively inhibited LPS-induced TNF-alpha production with an ED50 of approximately 10 μmol/kg and a pharmacodynamic half-life of approximately 8 hours. It also significantly reduced leukocyte infiltration in a lung inflammation model and attenuated paw swelling in a delayed-type hypersensitivity model, highlighting its efficacy as an anti-inflammatory agent through MC-1R modulation .
    BMS-470539
  • HY-N10623
    5-epi-Arvestonate A

    		Tyrosinase Cancer
    5-epi-Arvestonate A is a sesquiterpenoid isolated from the whole plants of Seriphidium transiliense. 5-epi-Arvestonate A promotes melanogenic production by activating the transcription of microphthalmia-associated transcription factor (MITF) and tyrosinase family genes. 5-epi-Arvestonate A inhibits the expression of IFN-γ-chemokine through the JAK/STAT signaling pathway in immortalized human keratinocyte (HaCaT) cells .
    5-epi-Arvestonate A
  • HY-W272217R
    Octacosane (Standard)

    n-Octacosane (Standard); NSC 5549 (Standard)

    		 Reference Standards Endogenous Metabolite Bacterial Inflammation/Immunology Cancer
    Octacosane (Standard) is the analytical standard of Octacosane. This product is intended for research and analytical applications. Octacosane is an endogenous metabolite with antibacterial activity. Octacosane shows high cytotoxicity against murine melanoma B16F10-Nex2 cells besides inducing protection against a grafted subcutaneous melanoma. Octacosane has the larvicidal activity against mosquito Culex quinquefasciatus with the LC50 concentration of 7.2 mg/l .
    Octacosane (Standard)
  • HY-120241
    Reticulol

    K 251-1

    		 Phosphodiesterase (PDE) Cancer
    Reticulol (K 251-1) is an inhibitor of cyclic adenosine 3', 5'-monophosphate phosphodiesterase. Reticulol shows antitumor activity independent with cell cycle arrest or apoptosis. Reticulol inhibits cell growth of murine melanoma cells and human lung tumor cells. Reticulol protects its lung metastasis via the bloodstream by inhibiting the growth of B16F10 melanoma .
    Reticulol
  • HY-N14435
    Pradimicin Q

    		Antibiotic Fungal Infection
    Pradimicin Q is an antibiotic. The cytotoxicity (IC50) to human colon HCT-116 cells and murine melanoma B16-F10 cells are 75 and 100 μg/mL, respectively .
    Pradimicin Q
  • HY-130116A
    IACS-8779 disodium

    		STING Cancer
    IACS-8779 disodium is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy. IACS-8779 disodium shows robust activation of the STING pathway in vitro and a superior systemic anti-tumor response in the B16 murine model of melanoma .
    IACS-8779 disodium
  • HY-77813S
    Benzyl isothiocyanate-d7

    		Isotope-Labeled Compounds Bacterial Apoptosis Antibiotic Endocrinology Cancer
    Benzyl isothiocyanate-d7 is the deuterium labeled Benzyl isothiocyanate. Benzyl isothiocyanate is a member of natural isothiocyanates with antimicrobial activity . Benzyl isothiocyanate potent inhibits cell mobility, migration and invasion nature and matrix metalloproteinase-2 (MMP-2) activity of murine melanoma cells .
    Benzyl isothiocyanate-d7
  • HY-153154
    COMC-6

    2-Crotonyloxymethyl-2-cyclohexenone

    		 Glyoxalase (GLO) Cancer
    COMC-6 is an anticancer agent and can be used for study of cancer .
    COMC-6
  • HY-108444
    (Z)-FeCP-oxindole

    		VEGFR Cancer
    (Z)-FeCP-oxindole is a selective human vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with an IC50 value of 200 nM. (Z)-FeCP-oxindole can significantly inhibit VEGFR1 and PDGFRa or b at 10 μM. (Z)-FeCP-oxindole has some anticancer activity, acting on B16 murine melanoma lines with IC50 less than 1 μM .
    (Z)-FeCP-oxindole
  • HY-108444A
    (E)-FeCP-oxindole

    		VEGFR Cancer
    (Z)-FeCP-oxindole is a selective human vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with an IC50 value of 200 nM. (Z)-FeCP-oxindole can significantly inhibit VEGFR1 and PDGFRa or b at 10 μM. (Z)-FeCP-oxindole has some anticancer activity, acting on B16 murine melanoma lines with IC50 less than 1 μM .
    (E)-FeCP-oxindole
  • HY-W001939R
    4-Acetylbenzoic acid (Standard)

    		Biochemical Assay Reagents Reference Standards Cancer
    4-Acetylbenzoic acid (Standard) is the analytical standard of 4-Acetylbenzoic acid. This product is intended for research and analytical applications. 4-Acetylbenzoic acid is a Zn(II) complex. 4-Acetylbenzoic acid is a derivative of benzoic acid that is commonly used in chemical synthesis. 4-Acetylbenzoic acid has an IC50 of 331.3 μM in murine L929 fibroblasts and an IC50 of 176 μM in metastatic melanoma B16 F10 cell lines .
    4-Acetylbenzoic acid (Standard)
  • HY-149523
    Anticancer agent 157

    		Apoptosis NO Synthase Caspase Inflammation/Immunology Cancer
    Anticancer agent 157 (compound 15) is a NO inhibitor (IC50=0.62 μg/mL) with anti-inflammatory and anticancer activities. Anticancer agent 157 can bind to iNOS (inducible NO synthase) and caspase 8, causing nuclear fragmentation and chromatin condensation, inducing apoptosis. Anticancer agent 157 inhibits HT29 colon cancer cells (IC50=2.45 μg/mL), Hep-G2 liver cancer cells (IC50=3.25 μg/mL), and B16-F10 murine melanoma cells (IC50=3.84 μg/mL) .
    Anticancer agent 157
  • HY-N10337
    Norjuziphine

    (-)-Norjuziphine

    		 Drug Derivative Cancer
    Norjuziphine ((-)-Norjuziphine) is an alkaloid found in the lotus flower (Nelumbo nucifera). Norjuziphine inhibits the melanogenesis of murine B16 melanoma 4A5 cells stimulated by Theophylline (HY-B0809) (IC50=14.4 μM). Norjuziphine is promising for research of skin whitening and related skin pigmentation diseases .
    Norjuziphine
  • HY-180555
    SN38-(PEG)2-Pom-α

    		PROTACs STING Inflammation/Immunology Cancer
    SN38-(PEG)2-Pom-α is a selective PROTAC RPL15 degrader. SN38-(PEG)2-Pom-α induces ubiquitin-mediated degradation of RPL15 without affecting TOP1. SN38-(PEG)2-Pom-α induces damage-associated molecular pattern (DAMP) secretion from cancer cells, which activated cGAS-STING signaling in dendritic cells. SN38-(PEG)2-Pom-α enhances anti-PD-1 immunotherapy in a murine melanoma tumor model expressing human CRBN. SN38-(PEG)2-Pom-α can be used for melanoma research .
    SN38-(PEG)2-Pom-α
  • HY-181967
    PROTAC PARP1 degrader-5

    		PROTACs PARP DNA/RNA Synthesis PD-1/PD-L1 Cancer
    PROTAC PARP1 degrader-5 is a PARP1 PROTAC degrader with a DC50 of 0.12 μM. PROTAC PARP1 degrader-5 hijacks the ubiquitin-proteasome system via catalytic ternary complex formation to drive sustained PARP1 degradation. PROTAC PARP1 degrader-5 induces DNA damage, drives marginal cytosolic double-stranded DNA accumulation in tumor cells, and up-regulates PD-L1 surface expression in tumor cells. PROTAC PARP1 degrader-5 shows tumor growth inhibition activity in murine melanoma models when encapsulated in lipid nanoparticles. PROTAC PARP1 degrader-5 can be used for the research of cancer, such as melanoma .
    PROTAC PARP1 degrader-5
  • HY-180419
    SF-3-030

    		ERK Apoptosis c-Myc Inflammation/Immunology Cancer
    SF-3-030 is a potent, selective and non-ATP competitive ERK1/2 inhibitor. SF-3-030 selectively induces apoptosis in melanoma cells containing mutated BRaf and constitutively active ERK1/2 signalling. SF-3-030 mitigates multiple features of asthma in a murine model of asthma. SF-3-030 can be used for the research of asthma and melanomasup .
    SF-3-030
  • HY-N2307B
    (R)-Lirinidine

    (-)-Lirinidine

    		 Melanocortin Receptor Cancer
    (R)-Lirinidine ((-)-Lirinidine) is an aporphine-type alkaloid found in the flower buds and leaves of Nelumbo nucifera. (R)-Lirinidineand inhibits melanogenesis with an IC50 of 19.3 μM. (R)-Lirinidine exerts cytotoxic effects at 100 μM .
    (R)-Lirinidine
  • HY-181120
    Antibacterial agent 319

    		Bacterial Infection Cancer
    Antibacterial agent 319 is an antibacterial and antitumor agent. Antibacterial agent 319 exhibits activity against E. coli and S. aureus. Antibacterial agent 319 also inhibits the growth of melanoma cells. Antibacterial agent 319 can be used in research on tumor bacterial infections such as melanoma .
    Antibacterial agent 319
  • HY-108444R
    (Z)-FeCP-oxindole (Standard)

    		Reference Standards VEGFR Cancer
    (Z)-FeCP-oxindole (Standard) is the analytical standard of (Z)-FeCP-oxindole (HY-108444). This product is intended for research and analytical applications. (Z)-FeCP-oxindole is a selective human vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with an IC50 value of 200 nM. (Z)-FeCP-oxindole can significantly inhibit VEGFR1 and PDGFRa or b at 10 μM. (Z)-FeCP-oxindole has some anticancer activity, acting on B16 murine melanoma lines with IC50 less than 1 μM .
    (Z)-FeCP-oxindole (Standard)
  • HY-172200A
    PD-L1/HDAC6-IN-1 TFA

    		PD-1/PD-L1 HDAC Inflammation/Immunology Cancer
    PD-L1/HDAC6-IN-1 TFA is an orally active dual inhibitor of PD-L1 and HDAC6, with IC50 values of 26.8 nM and 78 nM, respectively. PD-L1/HDAC6-IN-1 TFA binds to human and murine PD-L1 proteins with high affinity, while it reduces STAT3 phosphorylation and downregulates PD-L1 expression by inhibiting HDAC6, thus blocking the PD-1/PD-L1 interaction. PD-L1/HDAC6-IN-1 TFA exhibits potent anti-tumor activity in a mouse melanoma model. PD-L1/HDAC6-IN-1 is suitable for research on tumor immune regulation related to melanoma .
    PD-L1/HDAC6-IN-1 TFA
  • HY-185150
    PMEG

    9-(2-Phosphonylmethoxy)ethylguanine

    		 DNA/RNA Synthesis CMV Infection Inflammation/Immunology Cancer
    PMEG is a nuclear DNA polymerases α, δ, and ε inhibitor that causes DNA chain termination, inhibits DNA synthesis, induces cytotoxicity in dividing cells. PMEG is an acyclic nucleotide phosphonate that forms an active phosphorylated metabolite, PMEG diphosphate, within cells. PMEG has activity against leukemia and melanoma in rodent models. PMEG has poor cell permeability; its prodrug is Rabacfosadine (GS-9219) (HY-13640). PMEG shows antiviral activity against against various DNA virus infections including murine cytomegalovirus (MCMV) and human cytomegalovirus (HCMV). PMEG can be used for the research of non-hodgkin's lymphoma [1][2].
    PMEG
  • HY-183877
    YO-2

    		MDM-2/p53 Apoptosis Inflammation/Immunology Cancer
    YO-2 is a plasmin inhibitor and TP53 upregulator with anti-tumor and apoptosis-inducing activities. YO-2 upregulates the expression of TP53 and the tumor-suppressive miR-103/107, downregulates LRP1, and induces cellular DNA fragmentation and caspase cascade activation. YO-2 effectively blocks the growth of melanoma. YO-2 has been widely used in studies related to melanoma and colon cancer .
    YO-2
  • HY-181096
    PD-L1-IN-9

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-L1-IN-9 is a PD-L1 inhibitor with an IC50 of 110.85 nM. PD-L1-IN-9 has a Kd of 319 nM for human PD-L1 and a Kd of 450 nM for murine PD-L1. PD-L1-IN-9 blocks the PD-1/PD-L1 interaction, restores T cell-mediated anti-tumor immunity, and induces PD-L1 degradation in tumor tissues. PD-L1-IN-9 exhibits anti-tumor activity and can be used in the research of tumors such as melanoma .
    PD-L1-IN-9
  • HY-181916
    BXY-14

    		Toll-like Receptor (TLR) PD-1/PD-L1 Inflammation/Immunology Cancer
    BXY-14 is a TLR2 agonist and vaccine adjuvant. BXY-14 significantly downregulates the expression of intratumoral PD-L1 in mouse models. BXY-14 acts as a vaccine adjuvant to induce antibody responses. BXY-14 exhibits synergistic efficacy when combined with the anti-PD-L1 monoclonal antibody Atezolizumab (HY-P9904) in mouse models of melanoma, and prolongs overall survival. BXY-14 is applicable to research related to melanoma .
    BXY-14
  • HY-P11777
    AG73

    		MMP SDCBP Cardiovascular Disease Neurological Disease Cancer
    AG73 is a polypeptide. AG73 is derived from the G domain of the Laminin α1 chain. AG73 binds heparin, Syndecan-1 and Syndecan-4. AG73 promotes the adhesion of various cells, induces the differentiation of salivary gland acinar cells, stimulates neurite outgrowth, secretion of matrix metalloproteinases and angiogenesis. AG73 retains its angiogenic activity when conjugated to chitosan membranes. AG73 can be used in the research of melanoma and ischemic injury .
    AG73
  • HY-P11759
    Myr-transportan-Cys

    		Drug Derivative Cancer
    Myr-transportan-Cys is a derivative of the cell-penetrating peptide Transportan (HY-P1732), and its conjugated myristoyl group (Myr) enhances the interaction between the peptide and cell membranes. Myr-transportan-Cys integrates three key delivery functions: nucleic acid condensation, cell penetration, and endosomal escape. Myr-transportan-Cys can form immunostimulatory tandem peptide nanocomplexes (iTPNCs) for encapsulating and delivering immunostimulatory oligonucleotide cargos to tumors .
    Myr-transportan-Cys

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: